| Date | | Title |
| 07/28/10 |  | Allos Therapeutics Reports Second Quarter 2010 Financial Results |
| 07/28/10 | | Allos Therapeutics Announces Topline Results from Phase 2b Study of
FOLOTYN in Patients with Advanced Non-Small Cell Lung Cancer |
| 07/12/10 | | Allos Therapeutics to Report Second Quarter 2010 Financial Results on
July 28, 2010 |
| 06/17/10 | | Allos Therapeutics' Pralatrexate Granted Orphan Medicinal Product
Designation for the Treatment of Cutaneous T-Cell Lymphoma by the
European Commission |
| 06/11/10 | | Allos Therapeutics' FOLOTYN Shows Activity and Tolerability in Phase 1 Dose Finding Study in Patients with Relapsed or Refractory CTCL |
| 06/05/10 | | Allos Therapeutics Reports New Data Demonstrating that Responses to
FOLOTYN are Correlated with Prolonged Survival in Patients with Relapsed
or Refractory PTCL |
| 06/04/10 | | Allos Therapeutics to Present at Four Upcoming Investor Conferences |
| 06/01/10 | | Allos Therapeutics Announces FOLOTYN(R) Data
Presentations at the American Society of Clinical Oncology and the
Congress of the European Hematology Association |
| 05/20/10 | | Allos Therapeutics to Present at the Citi Investment Research Global
Health Care Conference |
| 05/18/10 | | Allos Therapeutics' Pralatrexate Granted FDA Orphan Drug Designation
for the Treatment of Bladder Cancer |
| 05/05/10 | | Allos Therapeutics Reports First Quarter 2010 Financial Results |
| 04/27/10 | | Allos Therapeutics Appoints Dr. Charles Morris as Chief Medical
Officer |
| 04/21/10 | | Allos Therapeutics to Report First Quarter 2010 Financial Results on
May 5, 2010 |
| 03/01/10 | | Allos Therapeutics Reports Fourth Quarter and Full Year 2009
Financial Results |
| 02/24/10 | | Allos Therapeutics to Participate in RBC Capital Markets Health Care
Conference |
| 02/17/10 | | Allos Therapeutics to Report Fourth Quarter and Full Year 2009
Results on March 1, 2010 |
| 02/03/10 | | Allos Therapeutics to Present at BIO CEO & Investor Conference |
| 01/06/10 | | Allos Therapeutics to Present at J.P. Morgan Healthcare Conference |
| 12/08/09 | | Allos Therapeutics' FOLOTYN(TM) Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma |
| 12/07/09 | | Allos Therapeutics' FOLOTYN(TM) Demonstrates Activity in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Treated with Stem Cell Transplant |
| 12/05/09 | | Allos Therapeutics Reports New Analyses of Data from Pivotal PROPEL Trial of FOLOTYN(TM) at 51st ASH Annual Meeting |
| 12/04/09 | | Allos Therapeutics Announces an Agreement with Idis for a Named Patient Program for FOLOTYN(TM) (pralatrexate injection) |
| 12/03/09 | | Allos Therapeutics to Launch Global Registry for Patients with Peripheral T-Cell Lymphoma at the American Society of Hematology Annual Meeting |
| 11/30/09 | | Allos Therapeutics Announces Issuance of U.S. Patent for FOLOTYN |
| 11/11/09 | | Allos Therapeutics Announces New Data on FOLOTYN(TM) to be Presented at the American Society of Hematology Meeting |
| 11/10/09 | | Allos Therapeutics to Present at Upcoming Conferences in November |
| 11/03/09 | | Allos Therapeutics Reports Third Quarter 2009 Financial Results |
| 10/26/09 | | Allos Therapeutics to Report Third Quarter 2009 Results on November 3, 2009 |
| 10/13/09 | | Allos Therapeutics Announces Closing of Public Offering |
| 10/07/09 | | Allos Therapeutics Announces Pricing of Public Offering of Common Stock |
| 10/05/09 | | Allos Therapeutics Announces Proposed Public Offering of Common Stock |
| 10/05/09 | | Allos Therapeutics Announces U.S. Availability of FOLOTYN(TM) (pralatrexate injection) for Relapsed or Refractory Peripheral T-Cell Lymphoma |
| 09/25/09 | | Allos Therapeutics' FOLOTYN(TM) First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma |
| 09/02/09 | | Allos Therapeutics Announces FDA Advisory Committee Recommends Accelerated Approval of FOLOTYN(TM) (pralatrexate) for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma |
| 09/01/09 | | Allos Therapeutics to Hold Post Advisory Committee Conference Call |
| 08/10/09 | | Allos Therapeutics Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma |
| 08/04/09 | | Allos Therapeutics Reports Second Quarter 2009 Financial Results |
| 07/23/09 | | Allos Therapeutics Launches Peripheral T-Cell Lymphoma Website |
| 07/22/09 | | Allos Therapeutics to Report Second Quarter 2009 Results on August 4, 2009 |
| 07/07/09 | | Allos Therapeutics Completes Enrollment in Randomized Phase 2b Trial of Pralatrexate in Patients with Advanced Non-Small Cell Lung Cancer |
| 06/03/09 | | Allos Therapeutics to Present at the 8th Annual Needham Life Sciences Conference |
| 05/30/09 | | Allos Therapeutics Reports Updated Data from Pivotal Phase 2 PROPEL Study of Pralatrexate at 45th ASCO Annual Meeting |
| 05/26/09 | | Allos Therapeutics Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status |
| 05/14/09 | | Allos Therapeutics Announces Updated Data from Pivotal Phase 2 PROPEL Study of Pralatrexate to be Presented at ASCO 2009 |
| 05/12/09 | | Allos Therapeutics to Present at the Eighth Annual JMP Securities Research Conference |
| 05/05/09 | | Allos Therapeutics Reports First Quarter 2009 Financial Results |
| 04/28/09 | | Allos Therapeutics to Report First Quarter 2009 Results on May 5, 2009 |
| 04/19/09 | | Allos Therapeutics' Pralatrexate Demonstrates Anticancer Activity in Multiple Cancer Cell Lines |
| 04/15/09 | | Allos Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2009 |
| 04/03/09 | | Allos Therapeutics Announces Closing of Common Stock Offering |
| 03/31/09 | | Allos Therapeutics Announces Pricing of Common Stock Offering |
| 03/25/09 | | Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma |
| 03/24/09 | | Allos Therapeutics Appoints David M. Stout to Its Board of Directors |
| 03/17/09 | | Allos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Bladder Cancer by the European Commission |
| 03/03/09 | | Allos Therapeutics Reports 2008 Results |
| 02/26/09 | | Allos Therapeutics to Report 2008 Results on March 3, 2009 |
| 02/03/09 | | Allos Therapeutics Announces Final Results from Pivotal PROPEL Trial of Pralatrexate in Patients with Peripheral T-cell Lymphoma |
| 02/02/09 | | Allos Therapeutics to Present at the 2009 BIO CEO & Investor Conference |
| 12/09/08 | | Allos Therapeutics to Present at the RBC Capital Markets 2008 Healthcare Conference |
| 12/07/08 | | Allos Therapeutics Announces Top Line Results from Pivotal Phase 2 PROPEL Trial of
Pralatrexate in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma |
| 12/06/08 | | Two Pralatrexate Studies Presented at the 50th Annual Meeting of the American Society of Hematology |
| 12/03/08 | | Allos Therapeutics to Host Analyst and Investor Briefing on Monday, December 8, 2008 |
| 12/01/08 | | U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma |
| 11/24/08 | | U.S. FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Diffuse Large B-Cell Lymphoma |
| 11/10/08 | | Four Pralatrexate (PDX) Studies to Be Presented at the 50th Annual Meeting of the American Society of Hematology |
| 11/05/08 | | Allos Therapeutics Reports 2008 Third Quarter Results |
| 11/04/08 | | Allos Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference |
| 10/30/08 | | Four Pralatrexate (PDX) Studies Accepted for Presentation at the 50th Annual Meeting of the American Society of Hematology |
| 10/29/08 | | Allos Therapeutics to Report Third Quarter 2008 Results on November 5, 2008 |
| 10/01/08 | | Allos Therapeutics to Present at the JMP Healthcare Focus Conference |
| 09/02/08 | | Allos Therapeutics to Present at the 3rd Annual Citi Biotech Day |
| 08/28/08 | | Allos Therapeutics to Present at the NewsMakers in the Biotech Industry Conference |
| 08/05/08 | | Allos Therapeutics Reports 2008 Second Quarter Results |
| 07/23/08 | | Allos Therapeutics to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference |
| 07/22/08 | | Allos Therapeutics to Report Second Quarter 2008 Results on August 5, 2008 |
| 07/21/08 | | Allos Therapeutics Initiates Phase 2 Study of PDX in Patients with Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder |
| 07/03/08 | | Allos Therapeutics to Present at the Collins Stewart Fourth Annual Growth Conference |
| 06/06/08 | | Allos Therapeutics to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference |
| 06/05/08 | | Allos Therapeutics Announces Interim Data from Phase 1 Study of PDX in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma |
| 05/29/08 | | Allos Therapeutics Announces Closing of Public Common Stock Offering |
| 05/23/08 | | Allos Therapeutics Announces Pricing of Public Offering of 10,800,000 Shares of Common Stock |
| 05/19/08 | | Allos Therapeutics Announces Public Offering of 9,000,000 Shares of Common Stock |
| 05/15/08 | | Allos Therapeutics Reports Interim Response and Safety Data from Pivotal Phase 2 PROPEL Trial |
| 05/07/08 | | Allos Therapeutics Reports First Quarter 2008 Financial Results |
| 05/06/08 | | Allos Therapeutics to Present at the Bank of America 2008 Healthcare Conference |
| 04/24/08 | | Allos Therapeutics to Report 2008 First Quarter Financial Results on May 7, 2008 |
| 04/22/08 | | Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma |
| 02/27/08 | | Allos Therapeutics Reports 2007 Results |
| 02/11/08 | | Allos Therapeutics to Report 2007 Results on February 27, 2008 |
| 01/29/08 | | Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference |
| 01/28/08 | | Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing |
| 01/07/08 | | Allos Therapeutics Initiates Phase 2b Study of PDX in Patients With Non-small Cell Lung Cancer |
| 12/27/07 | | Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma |
| 12/11/07 | | Allos Therapeutics to Present at the 2008 JPMorgan Healthcare Conference |
| 12/05/07 | | Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference |
| 11/29/07 | | Allos Therapeutics to Present at the 2007 BMO Capital Markets Focus on Healthcare Conference |
| 11/20/07 | | Allos Therapeutics to Present at the 2007 Lazard Capital Markets Healthcare Investor Conference |
| 11/12/07 | | Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma |
| 11/07/07 | | Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference |
| 11/05/07 | | Allos Therapeutics Reports Third Quarter 2007 Financial Results |
| 10/31/07 | | Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference |
| 10/25/07 | | Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference |
| 10/16/07 | | Allos Therapeutics to Report 2007 Third Quarter Financial Results on November 5, 2007 |
| 09/24/07 | | Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma |
| 09/13/07 | | Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference |
| 09/04/07 | | Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference |
| 08/15/07 | | Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma |
| 08/07/07 | | Allos Therapeutics Reports Second Quarter 2007 Financial Results |
| 07/18/07 | | Allos Therapeutics to Report 2007 Second Quarter Financial Results on August 7, 2007 |
| 06/25/07 | | Allos Therapeutics Selected to Join Russel 3000 Index |
| 06/19/07 | | Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer |
| 05/31/07 | | Allos Therapeutics Initiates Phase I/II Study of PDX and Gemcitabine in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease |
| 05/23/07 | | Allos Therapeutics Files Shelf Registration Statement |
| 05/08/07 | | Allos Therapeutics Reports First Quarter 2007 Financial Results |
| 05/01/07 | | Allos Therapeutics to Announce 2007 First Quarter Results on Tuesday, May 8 |
| 04/26/07 | | Allos Therapeutics Appoints Dr. Jeffrey R. Latts to Its Board of Directors |
| 04/19/07 | | Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European Commission |
| 03/20/07 | | Allos Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Medical Officer |
| 03/05/07 | | Allos Therapeutics Reports Fourth Quarter and 2006 Financial Results |
| 02/27/07 | | Allos Therapeutics to Report 2006 Fourth Quarter Financial Results on Monday, March 5 |
| 02/13/07 | | Allos Therapeutics to Present at Upcoming Investor Conferences |
| 02/02/07 | | Allos Therapeutics Announces Closing of Common Stock Offering |
| 01/30/07 | | Allos Therapeutics Announces Pricing of Underwritten Offering of 9,000,000 Shares of Common Stock |
| 01/08/07 | | Allos Therapeutics to Present at the 2007 JP Morgan Healthcare Conference |
| 01/08/07 | | Allos Therapeutics Appoints William R. Ringo to Its Board of Directors |
| 01/08/07 | | Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 Trial of Its Novel Antifolate PDX in Patients With Peripheral T-cell Lymphoma |
| 12/11/06 | | Results Reported at the American Society of Hematology Annual Meeting Affirm Impressive Activity of Allos Therapeutics' Novel Antifolate PDX in Patients with Peripheral T-Cell Lymphoma |
| 11/20/06 | | Allos Therapeutics Added to NASDAQ Biotech Index |
| 11/10/06 | | Updated Safety Analysis of Allos Therapeutics Phase 1/2 Study of PDX in Patients With Aggressive Lymphomas Demonstrates Decreased Incidence of Stomatitis With Vitamin Pre-Treatment and Weekly Dosing Schedule |
| 11/09/06 | | Allos Therapeutics Announces Presentation of Updated Results From Phase 1/2 Trial of PDX in Patients With Aggressive Lymphomas at the 2006 American Society of Hematology Annual Meeting |
| 11/06/06 | | Updated Analysis Demonstrates Long-Term Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Receiving Sequential Chemoradiotherapy |
| 11/03/06 | | Allos Therapeutics Reports Third Quarter 2006 Financial Results |
| 11/01/06 | | Allos Therapeutics to Announce 2006 Third Quarter Financial Results on Friday, November 3 |
| 10/31/06 | | Allos Therapeutics Announces Presentations on EFAPROXYN(TM) and PDX at Upcoming Scientific Conferences |
| 10/23/06 | | Allos Therapeutics Announces ENRICH Trial Update |
| 10/03/06 | | Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-cell Lymphoma |
| 08/29/06 | | Allos Therapeutics to Present at Upcoming Investor Conferences |
| 08/29/06 | | Allos Therapeutics Initiates Pivotal Phase 2 Study of PDX in Patients With Peripheral T-cell Lymphoma |
| 08/28/06 | | Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Study of EFAPROXYN(TM) in Women with Brain Metastases Originating from Breast Cancer |
| 08/07/06 | | Allos Therapeutics Reports Second Quarter 2006 Financial Results |
| 08/02/06 | | Allos Therapeutics Receives Special Protocol Assessment for Pivotal Phase 2 Study of the Company's Novel Antifolate PDX in Patients with Peripheral T-cell Lymphoma |
| 07/26/06 | | FDA Grants Orphan Drug Designation to Allos Therapeutics' Novel Antifolate PDX for the Treatment of T-cell Lymphoma |
| 06/14/06 | | Retrospective Analysis of Allos Therapeutics' Phase 3 REACH Study Finds Positive Correlation between Patient Outcomes and EFAPROXYN(TM) (efaproxiral) Exposure in Patients with Brain Metastases from Breast and Non-Small Cell Lung Cancers |
| 06/13/06 | | Allos Therapeutics Files Shelf Registration Statement |
| 06/07/06 | | Allos Therapeutics to Present at the 2006 Needham & Company Biotechnology Conference |
| 06/05/06 | | Allos Therapeutics Appoints James V. Caruso as Chief Commercial Officer |
| 06/05/06 | | Allos Therapeutics' EFAPROXYN(TM) Found to Reduce Tumor Hypoxia and HIF-1-alpha Expression in Human Breast Cancer Xenografts |
| 05/25/06 | | Allos Therapeutics Reports Restricted Stock Grant Under Nasdaq Marketplace Rule 4350 |
| 05/09/06 | | Allos Therapeutics Reports First Quarter 2006 Financial Results |
| 04/04/06 | | Interim Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 3 Trial |
| 03/10/06 | | Allos Therapeutics Appoints Paul L. Berns as President and CEO |
| 03/06/06 | | Allos Therapeutics Reports 2005 Financial Results |
| 03/01/06 | | Allos Therapeutics to Present at the 2006 Cowen Healthcare Conference |
| 02/14/06 | | Scheduled Combination of Allos Therapeutics' Pralatrexate Plus Gemcitabine Proves Superior to Methotrexate Plus Cytarabine in Models of Human Non-Hodgkin's Lymphoma |
| 02/01/06 | | Allos Therapeutics to Present at the 2006 BIO CEO & Investor Conference |
| 01/16/06 | | Allos Therapeutics Announces CEO Succession Plans |
| 01/03/06 | | Results Published in Journal of Clinical Oncology Affirm Survival Benefit of EFAPROXYN(TM) in Patients with Brain Metastases Originating From Breast Cancer |
| 12/12/05 | | Retrospective Analysis Finds EFAPROXYN(TM) Extends Survival With Quality of Life in Patients With Brain Metastases Originating From Breast Cancer |
| 12/12/05 | | PDX Shows Promising Activity in Patients With Resistant T-Cell Lymphomas |
| 11/17/05 | | Allos Therapeutics Appoints Timothy P. Lynch to Board of Directors |
| 11/17/05 | | Interim Phase 1 Data on RH1 Presented at AACR-NCI-EORTC Conference |
| 11/16/05 | | Data From Phase 1 Clinical Trial of PDX (Pralatrexate) to be Presented at American Society of Hematology Annual Meeting |
| 11/09/05 | | Allos Therapeutics Reports Third Quarter 2005 Financial Results |
| 11/08/05 | | Data on EFAPROXYN(TM) and RH1 to be Presented at Upcoming Scientific Conferences |
| 10/21/05 | | Allos Therapeutics Announces Dismissal of Securities Class Action Lawsuit |
| 10/13/05 | | Allos Therapeutics to Present at the 2005 BIO Investor Forum |
| 10/11/05 | | Allos Therapeutics Announces Withdrawal of European Marketing Authorization Application for REVAPROXYN(TM) |
| 09/22/05 | | Allos Therapeutics to Present at the UBS Global Life Sciences Conference |
| 09/07/05 | | Allos Therapeutics to Present at the Bear Stearns Healthcare Conference |
| 09/01/05 | | Results Published in Journal of Clinical Oncology Demonstrate Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Receiving Sequential Chemoradiotherapy |
| 08/08/05 | | Allos Therapeutics Reports Second Quarter 2005 Financial Results |
| 06/16/05 | | Allos Therapeutics and Hovione Enter Into Manufacturing Agreement for EFAPROXYN(TM) Bulk Drug Substance |
| 05/19/05 | | Allos Therapeutics Announces Stockholder Approval of Share Exchange |
| 05/19/05 | | Allos Therapeutics to Present at the Needham & Company Biotechnology Conference |
| 05/05/05 | | Allos Therapeutics Reports First Quarter 2005 Financial Results |
| 03/11/05 | | Allos Therapeutics to Present at SG Cowen's Healthcare Conference |
| 03/03/05 | | Allos Therapeutics Reports 2004 Financial Results |
| 03/03/05 | | Allos Therapeutics Announces $50 Million Financing |
| 01/20/05 | | Allos Therapeutics Initiates Phase 1 PDX Study in Patients With Non-Small Cell Lung Cancer |
| 01/06/05 | | Allos Therapeutics Announces Expansion of ENRICH Trial Into Europe |
| 12/16/04 | | Allos Therapeutics Licenses New Cancer Compound |
| 12/09/04 | | Allos Therapeutics Investigator Presents Updated Survival Results From Phase III REACH Study at San Antonio Breast Cancer Symposium |
| 11/17/04 | | Allos Therapeutics to Present at Credit Suisse First Boston's Healthcare Conference |
| 11/11/04 | | Allos Therapeutics Announces Presentation on EFAPROXYN(TM) at Chemotherapy Foundation Symposium XXII |
| 11/08/04 | | Allos Therapeutics Reports Third Quarter 2004 Financial Results |
| 11/04/04 | | Allos Therapeutics To Hold Third Quarter 2004 Financial Results Conference Call and Webcast on Tuesday, November 9 |
| 10/31/04 | | Updated Results of Allos' Phase 3 Reach Study Confirm Survival Benefit in Patients With Brain Metastases From Breast Cancer |
| 10/20/04 | | Allos Therapeutics to Present at Rodman & Renshaw Conference |
| 10/13/04 | | Allos Therapeutics Appoints Marc Graboyes as Vice President, General Counsel |
| 10/05/04 | | Response at Three-Months Post WBRT Found to be Statistically Significant Predictor of Survival in Largest Ever Randomized Study of Patients With Brain Metastases |
| 10/04/04 | | Prognostic Factors Influencing Survival in Patients with Brain Metastases Identified in Largest Ever Randomized Study |
| 08/03/04 | | Allos Therapeutics Receives Orphan Drug Designation From U.S. FDA for EFAPROXYN(TM) |
| 08/03/04 | | Reminder - Allos Therapeutics to Hold Q2 2004 Financial Results Conference Call and Webcast on Tuesday, August 3 |
| 08/03/04 | | Allos Therapeutics Reports Second Quarter 2004 Financial Results |
| 07/29/04 | | Allos Therapeutics to Hold Q2 2004 Financial Results Conference Call and Webcast on Tuesday, August 3 |
| 06/16/04 | | Allos Therapeutics Announces New Trade Names for Efaproxiral in the U.S. and Europe |
| 06/10/04 | | Allos to Present at Needham and Company's Third Annual Biotechnology Conference |
| 06/07/04 | | Data Presented at ASCO Demonstrate That Red Blood Cell Levels of Allos Therapeutics' RSR13 Correlate With Treatment Effect in Patients With Brain Metastases |
| 06/06/04 | | Data From Phase 3 Trial of Allos Therapeutics' RSR13 (efaproxiral) Presented at ASCO |
| 06/06/04 | | Analysis From Phase 3 Trial Suggests That Some Non-Small Cell Lung Cancer Patients With Brain Metastases May Benefit From Allos Therapeutics' RSR13 (Efaproxiral) |
| 06/04/04 | | Allos Therapeutics Files Application for European Marketing Approval of RSR13 (efaproxiral) |
| 06/02/04 | | Allos Therapeutics Receives FDA Approvable Letter for RSR13 (efaproxiral) |
| 05/28/04 | | Abstracts on Allos Therapeutics' RSR13 to Be Presented at American Society of Clinical Oncology Annual Meeting |
| 05/06/04 | | Allos Therapeutics Reports First Quarter 2004 Financial Results |
| 05/04/04 | | Allos Therapeutics to Hold Q1 2004 Financial Results Conference Call and Webcast on Thursday, May 6 |
| 05/03/04 | | FDA Advisory Committee Does Not Recommend Approval of RSR13 as Adjunctive Therapy for the Treatment of Brain Metastases Originating From Breast Cancer |
| 04/30/04 | | Allos to Discuss ODAC Panel Recommendation on Monday May 3, 2004 |
| 03/12/04 | | Allos NDA to be Reviewed by FDA Advisory Committee |
| 03/05/04 | | Allos Therapeutics Files Shelf Registration Statement |
| 02/12/04 | | Reminder - Allos Therapeutics Management Conference Call |
| 02/12/04 | | Allos Begins Phase 3 Study of RSR13 in Women With Brain Metastases From Breast Cancer |
| 02/12/04 | | Allos Therapeutics Reports Fourth Quarter and Year-End 2003 Results |
| 02/05/04 | | Allos Therapeutics Management Conference Call |
| 02/03/04 | | FDA Accepts Allos New Drug Application with Priority Review for RSR13 in Brain Metastases From Breast Cancer |
| 01/28/04 | | Allos Therapeutics Initiates Phase I Study of RSR13 in Locally Advanced Non-Small Cell Lung Cancer |
| 12/04/03 | | Allos Completes New Drug Application for Novel Treatment for Patients With Breast Cancer and Brain Metastases |
| 12/03/03 | | Arizona Cancer Center Investigator Presents Positive Survival and Quality of Life Data From RSR13 Phase 3 Study |
| 11/24/03 | | Allos Therapeutics Announces RSR13 Phase 3 Results in Patients With Breast Cancer and Brain Metastases Will Be Highlighted at the 26th Annual San Antonio Breast Cancer Symposium |
| 11/20/03 | | Allos Therapeutics Completes $12 Million Private Placement |
| 11/18/03 | | Allos Therapeutics Announces Presentation of Phase 1 Results of PDX in Patients With Advanced Non-Small Cell Lung Cancer |
| 11/17/03 | | Allos Therapeutics Announces Presentation of RSR13 Phase 3 Results in Brain Metastases at the Eighth Annual Meeting of the Society for Neuro-Oncology |
| 11/15/03 | | RSR13 Investigator Presented With National Tumor Foundation Research Award At Society for Neuro-Oncology Annual Meeting |
| 11/06/03 | | Reminder - Webcast Alert: Allos Therapeutics, Inc. Announces Third Quarter 2003 Financial Results Conference Call on the Web |
| 11/06/03 | | Allos Therapeutics Reports Third Quarter 2003 Financial Results |
| 10/31/03 | | Webcast Alert: Allos Therapeutics, Inc. Announces Third Quarter 2003 Financial Results Conference Call on the Web |
| 10/27/03 | | Allos Announces Settlement of Claims Against Durus Life Sciences Master Fund, Ltd. |
| 10/15/03 | | Satellite Symposium on Optimizing Outcomes of Therapy for Brain Metastases at ASTRO Meeting in Salt Lake City |
| 10/02/03 | | Allos Therapeutics Submits Second Part of Rolling New Drug Application For RSR13 for the Treatment of Brain Metastases From Breast Cancer |
| 08/12/03 | | Allos Therapeutics Announces Presentation of RSR13 Data in Non-Small Cell Lung Cancer at 10th World Conference on Lung Cancer |
| 08/07/03 | | Allos Therapeutics Reports Second Quarter 2003 Financial Results |
| 08/05/03 | | Allos Therapeutics Submits First Component of Rolling New Drug Application for RSR13 for the Treatment of Brain Metastases From Breast Cancer |
| 07/24/03 | | Webcast Alert: Allos Therapeutics Announces Q2 Financial Results Conference Call Webcast |
| 06/30/03 | | New Antifolate With Favorable Toxicity Profile Demonstrates Efficacy For Previously Treated Non-Small Cell Lung Cancer Patients |
| 06/17/03 | | Allos Therapeutics Announces Publication of Phase 2 Results Of Radiation Sensitizer in Journal of Clinical Oncology |
| 05/29/03 | | Allos Therapeutics Updates Operating Plan for 2003 |
| 05/29/03 | | Allos Therapeutics to Submit a New Drug Application for RSR13 for the Treatment of Brain Metastases From Breast Cancer |
| 05/07/03 | | Allos Therapeutics Reports First Quarter 2003 Financial Results and Adopts Stockholder Rights Plan |
| 04/23/03 | | Allos Reports Preliminary Results of Pivotal Phase 3 Clinical Trial of RSR13 in Brain Metastases |
| 04/22/03 | | Media Advisory - Allos Therapeutics to Hold Conference Call to Discuss Phase III Clinical Trial Results of its Radiation Sensitizer RSR13 |
| 02/13/03 | | Allos Therapeutics Reports Fourth Quarter and Year-End 2002 Results |
| 02/06/03 | | Allos Therapeutics Management Conference Call |
| 02/05/03 | | Allos Therapeutics, Inc. Announces Fourth Quarter and Year End Results Conference Call and Webcast |
| 02/04/03 | | Allos Therapeutics Clarifies Article on Johnson & Johnson 13G Filing |
| 01/07/03 | | Allos Therapeutics Licenses Phase 2 Cancer Compound |
| 01/03/03 | | Allos Therapeutics to Present at JPMorgan H&Q Healthcare Conference |
| 12/04/02 | | Allos Therapeutics Updates Regulatory Status of RSR13 |
| 11/07/02 | | Allos Therapeutics Reports Third Quarter 2002 Financial Results |
| 11/05/02 | | Allos Therapeutics to Present at SG Cowen Global Health Care Conference |
| 11/04/02 | | Allos Therapeutics Management Conference Call |
| 10/24/02 | | Allos Therapeutics, Inc. Announces Third Quarter Conference Call and Webcast |
| 10/02/02 | | Allos Therapeutics to Present at UBS Warburg Global Life Sciences Conference |
| 09/19/02 | | Allos Updates RSR13 Phase 2 Study Results in Non-Small Cell Lung Cancer At European Radiation Therapy Conference |
| 08/15/02 | | Allos Therapeutics Appoints David A. DeLong As Vice President, Sales and Marketing |
| 08/14/02 | | Allos Therapeutics Initiates Phase 1/2 Study of RSR13 In Advanced Cervical Cancer |
| 08/06/02 | | Allos Therapeutics Completes Enrollment of Pivotal Phase 3 Clinical Trial for RSR13 in Brain Metastases |
| 07/18/02 | | Allos Therapeutics Reports Second Quarter 2002 Financial Results |
| 07/10/02 | | Allos Therapeutics to Report Second Quarter Results and Host Investor Conference Call on Thursday, July 18, 2002, at 12:00 p.m. EDT - 10:00 a.m. MDT |
| 07/10/02 | | Allos Therapeutics Announces Second Quarter Conference Call and Webcast |
| 06/10/02 | | Allos Therapeutics Appoints Michael D. Casey, Former President and CEO Of Matrix, to Board of Directors |
| 05/31/02 | | DSMC Recommends Allos Therapeutics Proceed With Phase III Clinical Trial Of RSR13 in Patients With Brain Metastases |
| 05/20/02 | | Allos Updates Phase II Study Results in Non-Small Cell Lung Cancer at ASCO |
| 04/24/02 | | Allos Therapeutics Completes $15 Million Private Placement of Common Stock |
| 04/19/02 | | Allos Therapeutics Names Hudspeth, Vice President and Chief Financial Officer |
| 04/18/02 | | Allos Therapeutics Reports First Quarter 2002 Financial Results |
| 04/17/02 | | Allos Therapeutics Appoints Holz Director, Clinical Development |
| 04/15/02 | | Allos Therapeutics to Report First Quarter 2002 Financial and Host Investor Conference Call on Thursday, April 18, 2002 |
| 03/12/02 | | Allos Therapeutics In-Licenses Novel Chemoprotectant Compound |
| 02/11/02 | | Allos Therapeutics Reports Year-End 2001 Results |
| 10/18/01 | | Allos Therapeutics Reports Third Quarter 2001 Financial Results |
| 07/19/01 | | Allos Therapeutics Reports Second Quarter 2001 Financial Results |
| 04/25/01 | | Allos Therapeutics Reports First Quarter 2001 Financial Results |
| 03/12/01 | | Allos Therapeutics, Inc. to Present at the SG Cowen 21st Annual Health Care Conference in Boston |
| 02/14/01 | | Allos Therapeutics, Inc. Announces Year End 2000 Results |
| 10/19/00 | | Allos Therapeutics, Inc. Announces Third Quarter Financial Results |
| 07/20/00 | | Allos Therapeutics, Inc. Announces Second Quarter Financial Results |
| 05/02/00 | | Allos Therapeutics, Inc. Announces First Quarter Financial Results |
| 03/29/00 | | Allos Therapeutics, Inc. Raises $90 Million in Initial Public Offering Of Its Common Stock |
